Physician profile
Amanda L Ham
NPI 1912220237
$63,832.81
in general payments reported to CMS, 2019-2025
13 companies · $37K in 2025
The $37K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $954 · 2022: $9,472 · 2023: $11K · 2024: $5,707 · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Food and Beverage: $5,505 · Travel and Lodging: $3,716 · Consulting Fee: $3,188 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,827.50 |
| Food and Beverage | $5,505.28 |
| Travel and Lodging | $3,716.41 |
| Consulting Fee | $3,187.50 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $31,644.35 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28,619.80 | 2021-2025 | Caplyta |
| Alkermes, INC. | $836.96 | 2021-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $745.34 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $494.31 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $429.75 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $358.15 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $322.86 | 2022-2025 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $234.26 | 2022-2024 | Quviviq |
| Lundbeck LLC | $70.37 | 2021-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $43.49 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $21.40 | 2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Ham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.